摘要
急性心肌梗死(AMI)发生后,一系列复杂病理过程导致心脏结构和功能均发生改变,心脏纤维化(MF)形成后持续进展,导致心功能逐渐降低,预后不良。近年来中草药来源的活性成分因其结构稳定、药效确切逐步受到广泛关注,或许将为新药开发提供有价值的候选化合物。研究中药单体的作用和机制有利于寻找AMI后MF的有效治疗药物。目前已有多项实验研究发现,不同种中药单体均对AMI后MF的发生发展产生不同程度的阻抑作用且机制不同。根据中医理论对心肌梗死后心脏纤维化病机演变规律的认识,治疗药物可选取益气类、活血通络类、温阳类等,而对应的中药单体种类繁多、药效和作用机制不同,因此对于中药单体治疗AMI后MF的实验研究逐步广泛开展,并取得一定成果,日后仍需更多相关研究进行深入探索。
After the occurrence of acute myocardial infarction(AMI),a series of complex pathological processes lead to the changes of cardiac structure and cardiac function.Cardiac fibrosis(Myocardial Fibrosis,MF)continues to progress after its formation,leading to a gradual decrease in heart function and a poor prognosis.In recent years,active ingredients derived from Chinese herbal medicine have gradually received widespread attention due to their stable structure and precise efficacy,and may provide valuable candidate compounds for the development of new drugs.The study of the functions and mechanisms of the monomers of traditional Chinese medicine is helpful to find effective treatment drugs for MF after AMI.At present,many experimental studies have found that different kinds of traditional Chinese medicine monomers have different degrees of inhibition on the occurrence and development of MF after AMI,and the mechanisms are different.According to the understanding of the pathogenesis of cardiac fibrosis after myocardial infarction in traditional Chinese medicine,the therapeutic drugs can be selected from qi-invigorating drugs,blood-activating and collateral-activating drugs,warming-yang drugs,etc.The corresponding traditional Chinese medicine monomers are diverse,with different efficacy and mechanism of action.Therefore,the experimental research on the treatment of MF after the treatment of AMI with traditional Chinese medicine is gradually and extensively carried out,and certain results have been obtained.In the future,more relevant researches are still needed for in-depth exploration.
作者
李真
尹玉洁
刘依
韩宁馨
贾振华
LI Zhen;YIN Yujie;LIU Yi;HAN Ningxin;JIA Zhenhua(Hebei Medical University,Shijiazhuang 050017,China;Hebei Yiling Hospital,Shijiazhuang 050091,China;State Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine Medicines,Key Laboratory of National Administration of Traditional Chinese Medicine,Shijiazhuang 050035,China;Key Laboratory of National Administration of Traditional Chinese Medicine(Cardiovascular&Cerebrovascular Collateral Disease),Shijiazhuang 050035,China;Hebei Academy of Integrated Traditional Chinese and Western Medicine,Shijiazhuang 050035,China)
出处
《世界中医药》
CAS
2021年第11期1665-1670,共6页
World Chinese Medicine
基金
国家自然科学基金项目(81973692)——中医脉络学说指导NRG-1调控内皮间质转分化在心梗后心肌纤维化中的作用机制及干预研究
国家重点研发计划项目(2017YFC1700500)。
关键词
中药单体
急性心肌梗死
心脏纤维化
实验研究
益气
活血
通络
研究进展
Chinese medicine monomer
Acute myocardial infarction
Cardiac fibrosis
Experimental study
Yiqi
Promoting blood circulation
Dredging collaterals
Research progress
作者简介
李真(1993.07-),女,博士研究生在读,医师,研究方向:中西医结合防治心血管疾病研究,E-mail:1046823554@qq.com;通信作者:贾振华(1975.12-),男,博士,主任医师,研究方向:中西医结合防治心血管疾病研究,E-mail:jiatcm@163.com。
